Rubicon Research Limited (RUBICON) — Announcement(2 announcements)

· NSE 🔴 High Importance Neutral
1 Announcement 🔴 High Importance Neutral 📄 PDF

Rubicon Research Limited announced its intent to acquire an 85% stake in Arinna Lifesciences Limited for approximately INR 175.92 crores, marking a strategic entry into the CNS pharmaceutical segment and expanding its product portfolio and distribution network in India.

2 Announcement Neutral 📄 PDF

Rubicon Research announced its acquisition of an 85% stake in Arinna Lifesciences Limited, marking its entry into the Indian CNS formulations market and expanding its domestic distribution reach. extractedFields: { "documentType": "Press Release", "keyEvent": "Rubicon acquires 85% of Arinna Lifesciences to enter CNS formulations market", "financialImpact": "₹175.92 crores", "whatChanged": "₹56.7 crores revenue, 9.5 crores EBITDA (9M FY25)", "forwardGuidance": "Transaction expected to close within 30 days", "risksOrConcerns": null, "investorTakeaway": "This acquisition expands Rubicon’s market reach and growth potential in India’s CNS segment." } "sentiment": "neutral"

About Rubicon Research Limited (RUBICON)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,864.53 Cr

View full RUBICON stock details →

📡 Get AI alerts when RUBICON files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RUBICON — Free

📊 More RUBICON filings

See all RUBICON filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when RUBICON files new disclosures

Track RUBICON filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RUBICON — Free

Free account · 2 AI queries/day